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ABSTRACT: Despite extensive recent advances in understanding Alzheimer's dis- 
ease (AD) we are unable to noninvasively establish a definite diagnosis during life 
and cannot monitor the cerebral deposition of amyloid j? protein (Aj?) in living 
patients. We evaluated the use of 10H3, a monoclonal antibody Fab targeting Aj? 
protein 1-28 labeled with Tc-99m. Six subjects with probable AD were studied 
using single-photon emission computed tomography (SPECT) at times from 0-24 
hours following injection. Curves of radioactivity in blood demonstrate a half-life 
of the injected Fab of 2-3 hours. Images show uptake around the head in the scalp 
or bone marrow in all subjects. There is no evidence of cerebral uptake of the 
antibody. Scalp biopsies in all six patients demonstrate diffuse staining with lOH3 
of the scalp, a pattern indistinguishable from that found in controls. Evidence of 
amyloid deposition in the scalp in AD is not seen with other anti-Aj? antibodies, 
suggesting that 10H3 is cross-reacting with another protein. Further studies with 
anti-Aj? antibodies will require longer-lived radionuclides to detect cerebral uptake 
at later times after injection to allow for complete clearance from the blood. Alter- 
nately, imaging using labeled Aj? itself may provide a means for noninvasive tar- 
geting of cerebral amyloid. 
Remarkable advances have been made in our understanding of the mechanisms of 
amyloid /3 (AD) protein synthesis, cleavage, and aggregation, as well as pathways 
for tau protein phosphorylation responsible for neurofibrillary tangle formation. 
Three important genes with mutations causing Alzheimer's disease (AD) have now 
been discovered (chromosomes 21,14 and 1). There is also an important risk factor 
gene, believed to encode apolipoprotein E, on chromosome 19 which may be 
responsible for up to 30-40% of the attributable risk of AD. However, clinicians 
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still have no method available for the definite diagnosis of AD other than brain 
biopsy. Also, there is no method for evaluation of the progression of AP protein 
deposition in living patients. Patients with AD have intense accumulation of AP 
protein in senile plaque cores and in vessel walls in arteries, arterioles, and capillar- 
ies.’s2 Amyloid angiopathy was observed in 83% of 117 brains from AD patients in 
a study from the Consortium to Establish a Registry for AD.3 Vessel amyloid is 
accompanied by changes in vessel morphology, including thickening of the basement 
membrane and destruction of the smooth muscle layer. 
Brain imaging has been widely used in studies of AD. All current methods 
address aspects of the disease that are not central to the key pathogenetic mecha- 
nisms. We can study regional glucose metabolism, cerebral blood flow, oxygen 
metabolism, neuroreceptor density, and neurotransmitter uptake in the disease, but 
these important indices of brain function do not reflect primary disease mechanisms 
in AD. A method to allow for quantitative detection of cerebral amyloid deposits 
is needed. Anti-amyloid antibodies showing great affinity for the A/3 protein have 
added insights to our understanding of amyloid deposition in the brain in studies 
performed in vitro. We have hypothesized4-12 that intravenously injected anti-amy- 
loid antibodies will have access to vascular sites of amyloid deposition because of 
the extensive presence of AD in vessel walls.I3 We do not believe that the blood-brain 
barrier in AD is sufficiently broken down to allow for intravenously administered 
antibody to enter the brain parenchyma and label amyloid in neuritic plaque cores. 
Our hypothesis is that injected anti-amyloid antibodies will label sites of amyloid 
beta deposition in the endothelium of brain vessels on the blood side of the blood- 
brain barrier.”*12 
One considerable issue in this approach is to develop a ligand which has rapid 
blood clearance so that the binding of the antibody to vessel walls can be detected 
after clearance of the label from the intracerebral blood pool (which amounts to 
approximately 5% of brain intracranial volume). For this reason we have fragmented 




Antibody 10H3 was developed in a murine ascites system targeting amyloid AP 
1-28 using a synthetic antigen.11)’4x15 The antibody was evaluated, prepared, and 
mass-produced to GMP standards as previously des~ribed.’~,‘~ Antibody 10H3 was 
chosen because of excellent characteristics in labeling plaque and vessel amyloid 
in ~ i t ~ ~ . l I , 1 4 , 1 5  
Fractionation and Technetium Labeling 
Fab fragments were obtained using enzymatic methods and were labeled with 
generator-produced Tc-99m using the diamine dimercaptide bifunctional chelating 
system, as described by Fritzberg and associates“ and implemented by the NeoRx 
Corp., Seattle, WA. 
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Toxicity, Biodistribution, and Flow Cytometry 
Hematology, blood chemistry and histopathology was tested in adult Sprague- 
Dawley rats. Binding of the Fab to human white and red cells was tested using 
flow cytometry. 
Subjects 
Six patients were studied [mean age 73 (SD 10) years]. Three were male and 
three female. All patients had probable AD according to NINCDS-ADRDA crite- 
ria. Mini-mental Status Examination testing showed a mean score of 15 (SD 8, 
range 4-25). Autopsy material taken from control subjects was also studied histo- 
chemically. 
Imaging and Biodistribution 
Single-photon emission computed tomography (SPECT) was done using a Trio- 
nix scanner (Ohio). Labeled Fab was injected intravenously, mean dose 4.1 mg 
protein (SD 1.0, range 2.5-5), 33 mCi (SD 6.3, range 22-38.5). Biodistribution was 
determined by sampling blood at rapid periods after injection for 1 hour and then 
at %-hour intervals for 2 hours, and then at less frequent intervals for 24 hours. 
Patients were hospitalized in the Clinical Research Center at University Hospitals 
of Cleveland. 
Scalp Biopsies 
Scalp biopsy specimens were obtained in all six subjects using a standard derma- 
tological punch procedure following local anesthesia. Tissues were fixed in paraform- 
aldehyde lysin periodate, paraffin-embedded, and cut into 6-pM sections. Immuno- 
staining was performed with anti-amyloid antibodies 10H3 (AP 1-28), 4G8 (AD 
17-23), 3160 (AP 1-40), 6E10 (AD 1-17), and R1280 (AP 1-40). Sections were also 
counterstained with hematoxylin and eosin. Fixed but sucrose-protected cryostat 
sections were also immunostained in parallel to overcome paraffin-embedding arti- 
facts. 
IND #BB-5059 was received from the U.S. Food and Drug Administration, 
Division of Biological, for this investigation. Informed consent was obtained from 
all subjects or families, and the study was approved by the Investigational Review 
Board of the University Hospitals Cleveland. 
RESULTS 
The half-life of the injected technetium labeled 10H3 Fab is 2-3 hours in the 
plasma. SPECT images obtained immediately after injection demonstrate presence 
of the label in the cerebral blood pool in all subjects with diffuse uptake in the 
cerebrum. Images obtained at later intervals up to 17-24 hours demonstrate accumu- 
lation of the label in the scalp or bone marrow around the surface of the head. 
Because of the spatial resolution characteristics of SPECT, we are unable to localize 
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the precise anatomical site of this activity. There is no clear uptake of the label in 
the brain parenchyma even at longer periods after injection (24-36 hours). 
Scalp biopsy specimens demonstrate diffuse nonspecific staining with 10H3, but 
AP is not detected using any of the other anti-AP antibodies. Scalp tissue from 
controls also shows diffuse staining with 10H3 but no labeling with the other 
antibodies. Hair follicles are stained with 4G8 in both AD cases and controls. Hair 
follicle staining with 4G8 appears to represent binding to pigment. 
DISCUSSION 
A cardinal feature of AD is the deposition in cortex of large quantities of fibrillar 
AP protein.’-3 The presence of this protein in a P-pleated sheet comformation is 
used post mortem to establish the diagnosis, along with the detection of other 
pathological features, including neuropil threads, neurofibrillary tangles, granulo- 
vacuolar degeneration, and neuronal cell loss. There is no method available to 
image any of these cerebral pathologic features noninvasively during life. A novel 
approach is the use of immunochemistry in living patients by means of monoclonal 
antibodies targeting disease proteins, such as AP. 
In vivo radioimmunodetection has been successful in imaging sites of metastatic 
deposits in colon and breast cancer and melanoma.” A major problem with the 
use of antibody imaging in neurology is the blood-brain barrier, which generally 
excludes large molecules such as antibodies from entry. Workers dating back to 
Scholz (1938), who first noted amyloid infiltration in vessel walls in AD (“drusige 
Entartung”), have concluded from anatomical studies that blood-brain barrier 
function in AD should be abnormal? Degeneration of endothelium and thickening 
of the basement membrane with vascular degeneration has been observed in small 
vessels in AD, suggesting the presence of barrier changes.’ However, studies of 
blood-brain barrier functioning in living patients has not provided evidence of 
abnormalities.*”.*’ 
It has been proposed that the presence of normal cerebrospinal fluid total protein 
in AD is evidence for a normal blood-brain barrier. However, the relationship 
between cerebrospinal fluid and serum protein levels is dependent upon cerebrospi- 
nal fluid flow, and cerebrospinal fluid flow has been found to diminish with aging.22 
The integrity of the blood-brain barrier in Alzheimer’s disease remains an open 
issue. 
Anatomical studies have shown the proximity of AP deposits to the endothelium 
of capillaries, suggesting that circulating anti-amyloid antibodies would have access 
to antigen sites without the necessity of passing through the blood-brain barrier. 
The diamine dimercaptide method was used to label the monoclonal antibody 10H3 
with technetium-99m with high specificity and stability. An Fab fragment was used 
because it is less immunogenic and has a shorter circulation time than intact anti- 
body. The 6-hour physical half-life of Tc-99x11 may not be sufficient to allow for 
detection of label in brain beyond 18-24 hours. 
We found uptake of labeled anti-amyloid antibody 10H3 around the head. Scalp 
biopsies did not demonstrate evidence of AP infiltration of scalp. Conflicting results 
regarding the presence of AP in skin in AD and controls have been reported.” 
Use of antibodies labeled with longer-lived radionuclides such as iodine-131 
may allow for detection of intravascular binding of monoclonal antibodies to cere- 
bral amyloid in Alzheimer’s disease. A further approach is suggested by novel 
experiments demonstrating binding of labeled A 0  itself to cerebral amyloid in 
246 ANNALS NEW YORK ACADEMY OF SCIENCES 
AD.24-29 Zlokovic and colleagues have reported that AP coupled to apolipoprotein 
J crosses the blood-brain barrier better than native A p  or Ap coupled to apolipo- 
protein E.28 Ghilardi et al. infused aged squirrel monkeys with I-125-labeled A0 
via the carotid artery and demonstrated labeling of cerebral amyloid 
Labeling of cerebral amyloid in uiuo has also been demonstrated in squirrel monkeys 
with an intrathecally administered anti-amyloid antibody?O 
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